OMIC studies, even at the single-cell level, shed light on the molecular pathways working in glioblastoma cells, helping with the classification of GBM into subtypes [2,3,4] and leading to testing a variety of new potential therapeutic strategies, including (i) the administration of monoclonal antibodies, small molecules, and protein kinase inhibitors and (ii) the application of electric fields, intraoperative photodynamic therapy, and CAR-T immunotherapy (see the clinicaltrials.gov website). The gene discussed is WEE1; the disease is glioblastoma.